INFU Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of 5.12% compared to InfuSystems Holdings's net margin of -18.58%. InfuSystems Holdings's return on equity of 2.8% beat Retractable Technologies's return on equity of -16.83%.

InfuSystems Holdings has a consensus price target of --, signalling upside risk potential of 72.05%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that InfuSystems Holdings has higher upside potential than Retractable Technologies, analysts believe InfuSystems Holdings is more attractive than Retractable Technologies.

InfuSystems Holdings has a beta of 1.528, which suggesting that the stock is 52.819% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

InfuSystems Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystems Holdings pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

InfuSystems Holdings quarterly revenues are $35.3M, which are larger than Retractable Technologies quarterly revenues of $10.3M. InfuSystems Holdings's net income of $1.8M is higher than Retractable Technologies's net income of -$1.9M. Notably, InfuSystems Holdings's price-to-earnings ratio is 129.68x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystems Holdings is 1.33x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Tactile Systems Technology has a net margin of 5.12% compared to InfuSystems Holdings's net margin of 7.05%. InfuSystems Holdings's return on equity of 2.8% beat Tactile Systems Technology's return on equity of 7.89%.

InfuSystems Holdings has a consensus price target of --, signalling upside risk potential of 72.05%. On the other hand Tactile Systems Technology has an analysts' consensus of -- which suggests that it could grow by 38.49%. Given that InfuSystems Holdings has higher upside potential than Tactile Systems Technology, analysts believe InfuSystems Holdings is more attractive than Tactile Systems Technology.

InfuSystems Holdings has a beta of 1.528, which suggesting that the stock is 52.819% more volatile than S&P 500. In comparison Tactile Systems Technology has a beta of 1.203, suggesting its more volatile than the S&P 500 by 20.33%.

InfuSystems Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tactile Systems Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystems Holdings pays -- of its earnings as a dividend. Tactile Systems Technology pays out -- of its earnings as a dividend.

InfuSystems Holdings quarterly revenues are $35.3M, which are smaller than Tactile Systems Technology quarterly revenues of $73.1M. InfuSystems Holdings's net income of $1.8M is lower than Tactile Systems Technology's net income of $5.2M. Notably, InfuSystems Holdings's price-to-earnings ratio is 129.68x while Tactile Systems Technology's PE ratio is 26.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystems Holdings is 1.33x versus 1.46x for Tactile Systems Technology. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of 5.12% compared to InfuSystems Holdings's net margin of -4291.67%. InfuSystems Holdings's return on equity of 2.8% beat Catheter Precision's return on equity of -65.84%.

InfuSystems Holdings has a consensus price target of --, signalling upside risk potential of 72.05%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 429.24%. Given that Catheter Precision has higher upside potential than InfuSystems Holdings, analysts believe Catheter Precision is more attractive than InfuSystems Holdings.

InfuSystems Holdings has a beta of 1.528, which suggesting that the stock is 52.819% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

InfuSystems Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystems Holdings pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

InfuSystems Holdings quarterly revenues are $35.3M, which are larger than Catheter Precision quarterly revenues of $96K. InfuSystems Holdings's net income of $1.8M is higher than Catheter Precision's net income of -$4.1M. Notably, InfuSystems Holdings's price-to-earnings ratio is 129.68x while Catheter Precision's PE ratio is 0.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystems Holdings is 1.33x versus 1.01x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 5.12% compared to InfuSystems Holdings's net margin of -17.98%. InfuSystems Holdings's return on equity of 2.8% beat Xtant Medical Holdings's return on equity of -35.98%.

InfuSystems Holdings has a consensus price target of --, signalling upside risk potential of 72.05%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than InfuSystems Holdings, analysts believe Xtant Medical Holdings is more attractive than InfuSystems Holdings.

InfuSystems Holdings has a beta of 1.528, which suggesting that the stock is 52.819% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

InfuSystems Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystems Holdings pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

InfuSystems Holdings quarterly revenues are $35.3M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. InfuSystems Holdings's net income of $1.8M is higher than Xtant Medical Holdings's net income of -$5M. Notably, InfuSystems Holdings's price-to-earnings ratio is 129.68x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystems Holdings is 1.33x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.